IPCA Laboratories Limited (IPCALAB) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

IPCA Laboratories is a Mumbai-headquartered formulations and API maker with a ~2.08% domestic market share, a growing exports franchise and the recently integrated Unichem business. This Q2 FY27 print will speak to whether the raised FY27 guidance of 14-16% revenue growth and ~23% consolidated EBITDA margin holds, with freight inflation and material costs the key swing factors against the 22.88% Q1 margin print.

IPCA Laboratories Limited Q2 Results Date and Time

The Board of Directors will meet on 5 November 2026 to approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30 September 2026 (Regulation 29, SEBI LODR). The insider trading window under SEBI PIT remains closed from 1 October 2026 until 48 hours after the results, i.e., till 7 November 2026.

A conference call to discuss Q2 FY27 earnings and business update is scheduled for Thursday, 5 November 2026, 16:00-17:00 IST, hosted by Dam Capital Advisors Ltd (formerly IDFC Securities). Mr. A K Jain, Managing Director, and Mr. Harish Kamath, Corporate Counsel & Company Secretary, will represent the management.

What to expect from IPCA Laboratories Limited's Q2 FY27 results

The quarter tests whether IPCA's raised FY27 frame — consolidated revenue growth of 14-16% and a ~23% consolidated EBITDA margin — survives a Q2 in which freight and material costs ran hot while the rupee stayed weak. The domestic backdrop is the strongest in years: IPM value growth ran at 12-13.5% per month through July-September, with the Q2 FY27 IPM print of ~12% by value a six-quarter high led by a volume recovery, though IPCA's Q1 domestic formulations growth of 12.60% already trailed IPM's 13.5%.

The FX tailwind management flagged — rupee depreciation contributed ~5% of Q1's 21% turnover growth, with the currency holding a weak Rs. 95-96 band all quarter — was guided to last 'at least the next two quarters', covering precisely this one.

On the US side, the Section 232 tariff regime effective 29 September 2026 explicitly excludes generics, so no tariff repricing of the Rs. 1,567 Cr FY26 US franchise should be in the quarter, and ANDA approvals continued (amlodipine besylate approved 22 Sep 2026 for Ipca; alprazolam and celecoxib approvals for Unichem in July and October).

The contested question is the margin line: global container freight remained ~132% above February levels with the Strait of Hormuz disruption still live, even as composite rates drifted lower late in the quarter, and management itself had cautioned that Q2 could be a peak-margin quarter — making the ~23% FY27 margin guide the key thing the call will be probed on.

Key Things To Watch

Performance vs guidance tracking: Management raised FY27 guidance at the Q1 call on 14 August 2026; here is what to check against each item.

• Consolidated revenue growth — 14-16% for FY27 (raised from 12-13%) — check H1 run-rate vs the raised guide
• Consolidated EBITDA margin — ~23% for FY27 (raised from 22%) — check Q2 margin vs the 22.88% Q1 FY27 print
• Institutional business — Rs. 260-300 Cr for FY27 — check run-rate ex the ~Rs. 40 Cr Q1 shipment slip
• Unichem growth / margin — 10% growth / 12-13% EBITDA margin for FY27 — check Q2 Unichem EBITDA vs ~11% in Q2 FY26
• Capex — Rs. 700-800 Cr for FY27 plus ~Rs. 100 Cr biotech spend — check deployment progress
• Long-term debt — Rs. 70 Cr term loan outstanding by FY27 year-end — check balance sheet
• FY28 guidance — to be provided at the time of the Q4 FY27 results announcement — confirm timing

Margin seasonality and freight headwind

• Whether Q2 FY27 margins hold above the 22.88% Q1 print, given management previously called Q2 FY26 a potential peak-margin quarter as domestic business typically slows in Q3/Q4
• Whether tripled freight rates on South America (South America $3,000 to $9,000-$10,000), US ($7,000-$7,500 to $12,500-$13,000) and Europe ($3,000 to $5,500) lanes dented Q2 margins, and management's updated freight commentary
• Whether the rupee-benefit narrative (~5% of Q1's 21% turnover growth) is described as persisting or fading

Institutional generics run-rate

• Q1's +107% institutional generics print included ~Rs. 40 Cr of shipments that slipped from March to April; underlying quarterly run-rate is ~Rs. 72 Cr ex-slip
• How the ex-slip run-rate tracks against the Rs. 260-300 Cr FY27 guided range

Unichem US recovery and held guidance

• Whether the US market-share recovery management flagged for '2-3 quarters' from Q3 FY26 is visible in Q2
• Whether management now revisits the held 10% growth / 12-13% EBITDA margin guidance — A.K. Jain had said, 'Unichem guidelines, I'm not revising right now. Let's see for some more quarters how it performs'

Biotech and biosimilar milestones

• Progress from engineering batches (2 products completed) toward validation, with initial stability results expected by mid-next year
• Clinical work slated to start next financial year; ~Rs. 100 Cr FY27 investment across 7 pipeline candidates, with biosimilar revenues expected FY29-FY30